AUS
NZ
UK
CA
USA
IND
Highlights
- Ryoncil becomes the first FDA-approved mesenchymal stromal cell therapy for SR-aGvHD.
- Mesoblast (ASX:MSB) expands treatment options for children with severe graft-versus-host disease.
- The company to debut on the Nasdaq Biotechnology Index this December.
Regenerative medicine company Mesoblast (ASX:MSB) has achieved a significant milestone with the US Food and Drug Administration (FDA) granting approval for its Ryoncil therapy. This innovative treatment is designed for children suffering from steroid-refractory acute graft-versus-host disease (SR-aGvHD), a condition arising after bone marrow or stem cell transplants. This approval marks the first mesenchymal stromal cell therapy available in the US for this critical condition.
Ryoncil, derived from bone marrow cells, will be available as an intravenous infusion across US transplant centers and hospitals. Its approval represents a breakthrough for patients and families battling SR-aGvHD, a condition associated with poor outcomes and high mortality rates.
Advancing Late-Stage Products
Mesoblast CEO, Dr. Silviu Itescu, welcomed the FDA's decision, emphasizing the company’s dedication to addressing unmet needs in the graft-versus-host disease community. The company is also pursuing approvals for additional late-stage products, including Revascor for cardiovascular disease and rexlemestrocel-L for inflammatory pain. Furthermore, Mesoblast aims to expand Ryoncil’s applications to other inflammatory conditions in both pediatric and adult patients.
Promising Clinical Outcomes
Clinical data highlights Ryoncil’s potential to transform treatment outcomes. Research indicates that approximately 10,000 individuals in the US undergo allogeneic bone marrow transplants annually, including 1,500 children. Nearly half of these patients develop acute graft-versus-host disease (aGvHD), and a significant proportion do not respond to steroid therapies.
In a clinical trial involving children with SR-aGvHD, where most had severe Grade C or Grade D disease, Ryoncil achieved an overall response rate of 70% within 28 days. The majority of patients, over 85%, successfully completed their treatment without interruptions, showcasing the therapy’s safety and efficacy.
Expanding Therapeutic Potential
Ryoncil’s immunomodulatory properties also open doors for broader applications, including treatment-resistant inflammatory bowel disease and SR-aGvHD in adults. The therapy’s ability to release anti-inflammatory factors helps counteract immune responses, reducing the damaging effects of inflammation.
Nasdaq Listing on the Horizon
In another notable development, Mesoblast (MSB) is set to join the Nasdaq Biotechnology Index on December 23. This inclusion reflects the company’s growing prominence in the biotechnology sector, meeting eligibility criteria such as trading volume and market capitalization.
Mesoblast’s FDA approval for Ryoncil underscores its commitment to advancing regenerative therapies and addressing critical medical needs across various conditions.
